Adlai Nortye (ANL) Current Deferred Revenue (2024 - 2025)
Adlai Nortye (ANL) reported Current Deferred Revenue of $5.0 million for Q2 2025, little changed year-over-year from $5.0 million in Q2 2024, and little changed on a QoQ basis from $5.0 million in Q4 2024.
Adlai Nortye (ANL) has 2 years of Current Deferred Revenue data on file, last reported at $5.0 million in Q2 2025.
- Quarterly Current Deferred Revenue changed 0.0% year-over-year to $5.0 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $5.0 million (changed 0.0% YoY) and the FY2024 annual result came in at $5.0 million, changed N/A from the prior year.
- Current Deferred Revenue steadied at $5.0 million in Q2 2025 per ANL's latest filing, from $5.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $5.0 million in Q2 2024 and bottomed at $5.0 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |